FGFR3 Inhibitor

LOXO-435

Type of Alteration(s)
Point mutations*
Alteration(s) of Interest
FGFR3 R248C
FGFR3 S249C
FGFR3 G370C
FGFR3 Y373C
Methodology
Key Considerations
NGS (Tissue)
  • Suitable for broad-based genomic profiling that includes targets in addition to FGFR3
  • Full coverage of FGFR3 gene is preferred over hotspot sequencing
NGS (cfDNA)
  • Useful when tissue biopsy sample is limited/unavailable
  • Higher false negative rate than tissue-based NGS testing
PCR-based
  • Will detect selected mutations
*
Point mutations occur at higher frequency (15-20%) than fusions (2-3%)
List not exhaustive of all activating alterations
References
1. Robertson et al. Cell 2017;171(3):540-556 2. TCGA Research Network Nature 2014;507(7492):315-322 3. Nassar et al. JCO Precis Oncol 2018;16(2)

Check Clinical Trials information to see if patient qualifies

Need additional information or have a question:

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.